Carmot Therapeutics
Jan 19, 2018
Pandion bags $58M; Carmot Therapeutics grabs $15M; Innovent looks for IPO; Collaboration of Sandoz & Biocon
Pandion Therapeutics bags USD 58 million in series A Funding Focused on developing Targeted immune modulator drugs, Pandion Therapeutics has successfully grabbed USD 58 million in series A funding. The company is led by highly experienced professionals. Anthony Coyle (former senior vice president at Pfizer and globa...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
